1 / 6

Dry Eye Syndrome Therapeutics Pipeline Products Under Drug Profile Includes Product Description & Developmental Activiti

<br>The study analyzed that the dry eye syndrome therapeutics pipeline comprises approximately 50 drug candidates in different stages of development.<br>According to the research findings, most of the drug candidates of dry eye syndrome pipeline are being developed to be administered by topical route.<br><br>InSite Vision (A Sun Pharmaceutical Industries Ltd. company) is using DuraSite technology platform for the development of their drug candidates for the treatment of dry eye syndrome. DuraSite is a drug delivery vehicle that stabilizes small molecules in a polymeric mucoadhesive matrix.

NidhiNehani
Download Presentation

Dry Eye Syndrome Therapeutics Pipeline Products Under Drug Profile Includes Product Description & Developmental Activiti

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Dry Eye Syndrome Therapeutics Pipeline to Develop with Maximum Drugs Being Derived from Natural Sources

  2. Dry Eye Syndrome Therapeutics According to a new research report “Dry Eye Syndrome Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, Dry Eye Syndrome currently exhibits a pipeline with 50 drug candidates. Explore Report Description at: https://www.psmarketresearch.com/market-analysis/dry-eye-syndrome-therapeutics-pipeline-analysis Dry Eye Syndrome therapeutics pipeline in 2017 The study analyzed that the dry eye syndrome therapeutics pipeline comprises approximately 50 drug candidates in different stages of development.

  3. Dry Eye Syndrome Therapeutics Insights on pipeline segments According to the research findings, most of the drug candidates of dry eye syndrome pipeline are being developed to be administered by topical route. DuraSite technology platform for Dry Eye Syndrome drug development InSite Vision (A Sun Pharmaceutical Industries Ltd. company) is using DuraSite technology platform for the development of their drug candidates for the treatment of dry eye syndrome. DuraSite is a drug delivery vehicle that stabilizes small molecules in a polymeric mucoadhesive matrix.

  4. Dry Eye Syndrome Therapeutics Natural Sources are being used for the development of drugs in the Dry Eye Syndrome Therapeutics Pipeline The research found that various companies use natural sources for the development of dry eye syndrome therapeutics pipeline that includes, but not limited to, MC2 Therapeutics and RegeneRx Biopharmaceuticals, Inc. Some of the other key players developing drugs for the treatment of dry eye syndrome include Ocular Therapeutix, Inc., LTT Bio-Pharma, HanAllBioPharma Co., Ltd. and others.

  5. Dry Eye Syndrome Therapeutics Download report sample at: https://www.psmarketresearch.com/market-analysis/dry-eye-syndrome-therapeutics-pipeline-analysis/report-sample

  6. GET IN TOUCH THANK YOU! For information regarding permissions and other queries Kindly write to: US/Canada Toll-Free: 1-888-778-7886

More Related